Effect of prostaglandins E1, E2 and F2alpha on neutrophil aggregation.

Recently we have found that chemotactic factors stimulate neutrophils in suspension to aggregate. Because of an obvious analogy to platelet aggregation, we examined the influence of three prostaglandins on this process. Prostaglandins E1, E2 and F2alpha alone did not cause aggregation of the neutrophils but were able to partially inhibit the aggregation response induced by the synthetic chemotactic tripeptide, formyl-methionyl-leucyl-phenylalanine. The minimal inhibitory concentrations for prostaglandins E1, E2 and F2alpha were 10(-7), 10(-6) and 10(-5)M, respectively. These results are similar to those found for the prostaglandin-induced inhibition of platelet aggregation. It may be, therefore, that neutrophil aggregation, like platelet aggregation, is modulated by intracellular prostaglandins and other products of arachidonic acid metabolism.     

Investigation of prostaglandins in the culture supernatant of mononuclear cells and its influence on platelet aggregation.

The prostaglandins can be synthesized by many cells types. Cells of the immune system also metabolise arachidonic acid to prostaglandins. However, the specific class of immunocompetent cells that synthesize prostaglandins as well as the spectrum of arachidonic acid metabolides produced by these cells is not firmly established. The aim of our study was to investigate the behaviour of prostaglandins in the culture supernatant of mononuclear cells and the influence of this supernatant on platelet aggregation. Blood cells were separated from peripheral blood according to a modification of the procedure of B?yum. The level of prostaglandins was determined by means of radioimmunoassay kits. The PGF2 alpha concentrations were significantly higher in the culture supernatant (F) in comparison with supernatant (K) and (O). The supernatant of lymphocytes culture does not influence platelet aggregation. The highest concentrations of PGE1 and PGF2 alpha were noted at the 12 and 24 hours of the monocyte cultivation, however the lowest at the 36 and 48 hours. The supernatant obtained from monocyte cultivation at the 36 hours exert an independent effect on platelets aggregation, whereas at 24 and 48 hours it plays a role in platelet aggregation. The presented results may indicate the influence of monocytes on AA metabolism and platelet function.     

Effect of prostaglandins E1, E2 and F2α on neutrophil aggregation

Recently we have found that chemotactic factors stimulate neutrophils in suspension to aggregate. Because of an obvious analogy to platelet aggregation, we examined the influence of three prostaglandins on this process. Prostaglandins E₁, E₂ and F_2α alone did not cause aggregation of the neutrophils but were able to partially inhibit the aggregation response induced by the synthetic chemotactic tripeptide, formly-methionyl-leucyl-phenylalanine. The minimal inhibitory concentrations for prostaglandins E₁, E₂ and F_2α were 10⁻⁷, 10⁻⁶ and 10⁻⁵M, respectively. These results are similar to those found for the prostaglandin-induced inhibition of platelet aggregation. It may be, therefore, that neutrophil aggregation, like platelet aggregation, is modulated by intracellular prostaglandins and other products of arachidonic acid metabolism.     

Formation by phospholipase A2 of prostaglandins and thromboxane A2-like activity in the platelets of normal and essential fatty acid deficient rats. Comparison with effect on human and rabbit platelets

When rat platelets are incubated with phospholipase A2, thromboxane A2-like activity and prostaglandins are formed. The amounts are approximately similar, whether aggregation is induced after the incubation or not. No aggregation is observed when the platelets are incubated with phospholipase A2. In the platelets of essential fatty acid deficient rats, only small amounts of thromboxane A2-like acitivity and prostaglandins are formed. No formation of these substances occurs when human and rabbit platelets are incubated with phospholipase A2. The results indicate that formation of thromboxane A2-like activity enhances aggregation in rat platelets, but that aggregation is not induced.     

Prostaglandin receptors on human platelets. Structure-activity relationships of stimulatory prostaglandins.

1. Synthetic analogues of prostaglandins E2 or F2a (monocyclic bisenoic prostaglandins), like the endogenous prostaglandin endoperoxides (prostaglandins G2 and H2) from platelets, and like synthetic analogues of prostaglandin H2 (bicyclic bisenoic prostaglandins), can induce aggregation of human platelets, although prostaglandins E2 and F2a themselves are inactive. 2. All the prostanoid compounds that induce platelet aggregation release 5-hydroxytryptamine from platelet dense bodies, but do not release beta-N-acetylglucosaminidase from lysosomal granules. Arachidonic acid evokes a similar response. 3. All endoperoxide analogues tested (bicyclic compounds) were powerful platelet stimulants, and all active compounds (whether mono- or bi-cyclid) apparently acted via the same receptor as the endogenous prostaglandin endoperoxides. 4. The nature and stereospecificity of substituents at positions 11 and 15 (or 16) on prostaglandin E2 are critical determinants for platelet-stimulating activity: deoxy substitution at position 11 plus methylation at position 15 (or 16) produces a potent stimulant, particularly if the groups around C-15 are in the S configuration. 5. The effects of these structural modifications are apparently due to, at least in part, a change in side-chain conformation.     

Modulation of antioxidant enzyme activities, platelet aggregation and serum prostaglandins in rats fed spray-dried milk containing n-3 fatty acid

Spray-dried milk enriched with n-3 fatty acids from linseed oil (LSO) or fish oil (FO) were fed to rats to study its influence on liver lipid peroxides, hepatic antioxidant enzyme activities, serum prostaglandins and platelet aggregation. Significant level of α linolenic acid, eicosapentaenoic acid and docosahexaenoic acid were accumulated at the expense of arachidonic acid in the liver of rats fed n-3 fatty acid enriched formulation. The linseed oil and fish oil enriched formulation fed group had 44 and 112% higher level of lipid peroxides in liver homogenate compared to control rats fed groundnut oil enriched formulation. Catalase activity in liver homogenate was increased by 37 and 183% respectively in linseed oil and fish oil formulation fed rats. The glutathione peroxidase activity decreased to an extent of 25–36% and glutathione transferase activity increased to an extent of 34–39% in rats fed n-3 fatty acids enriched formulation. Feeding n-3 fatty acid enriched formulation significantly elevated the n-3 fatty acids in platelets and increased the lipid peroxide level to an extent of 4.2 to 4.5-fold compared to control. The serum thromboxane B₂ level was decreased by 35 and 42% respectively in linseed oil and fish oil enriched formulation fed rats, whereas 6-keto-prostaglandin F1α level was decreased by 17 and 23% respectively in linseed oil and fish oil enriched formulation fed rats. The extent and rate of platelet aggregation was decreased significantly in n-3 fatty acids enriched formulation fed rats. This indicated that n-3 fatty acids enriched formulation beneficially reduces platelet aggregation and also enhances the activities of hepatic antioxidant enzymes such as catalase and glutathione transferase.     

Formation by phospholipase A2 of prostaglandins and thromboxane A2-like activity in the platelets of normal and essential fatty acid deficient rats. Comparison with effect on human and rabbit platelets

When rat platelets are incubated with phospholipase A₂, thromboxane A₂-like activity and prostaglandins are formed. The amounts are approximately similar, whether aggregation is induced after the incubation or not. No aggregation is observed when the platelets are incubated with phospholinase A₂. In the platelets of essential fatty acid deficient rats, only small amounts of thromboxane A₂-like activity and prostaglandins are formed. No formation of these substances occurs when human and rabbit platelets are incubated with phospholipase A₂.The results indicate that formation of thromboxane A₂-like activity enhances aggregation in rat platelets, but that aggregation is not induced.     

Beclobrinic acid--a new hypolipidemic agent--inhibits in vitro human platelet activation by blocking prostaglandin synthesis

Effects and the mechanism of the antiplatelet actions of beclobrinic acid, free acid form of a new hypolipidemic agent beclobrate [(+)-2-[d-(P-chlorophenyl)p-tolyl)oxy)-2-methyl-butyrate), were examined using human platelets. Platelet-rich plasma (PRP) which has been prelabeled with (14C)-serotonin was incubated with beclobrinic acid (BBA) for one minute before the addition of various agonists. BBA (0.1-1.5 mM) inhibited platelet aggregation and serotonin secretion induced by ADP, epinephrine, arachidonic acid and collagen in a concentration dependent manner. BBA also inhibited arachidonic acid-induced production of malondialdehyde (MDA), a byproduct of prostaglandins, in a concentration dependent manner. However, up to 1.0 mM BBA did not inhibit platelet aggregation induced by U46619, a stable analog of prostaglandin H2. In other experiments BBA also blocked thrombin-induced release of (3H)-arachidonic acid from platelet phospholipids. These findings suggest that: (a) BBA inhibits platelet aggregation and serotonin secretion by inhibiting prostaglandin synthesis at two steps. First by interfering in the release of arachidonic acid from platelet phospholipids and second by inhibiting its conversion into prostaglandins; and (b) BBA does not inhibit the action of prostaglandins on human platelets.     

Stimulation and inhibition of biosynthesis of prostaglandins in human skin by some hydroxyethylated rutosides.

The effect of some hydroxyethylated rutosides on the biosynthesis of prostaglandins was studied in the microsomal fraction of human skin homogenates. Microsomes were incubated with mono-0-hydroxyethyl-7-rutoside (mono-7-HR), di-0-hydroxyethyl-7',4-rutoside (di-HR), tri-0-hydroxyethyl-7,3',4'-rutoside (tri-7,3',4'-HR), tetra-0-hydroxyethyl-5,7,3',4'-rutoside (tetra-HR) and a mixture of hydroxyethylated compounds (HR). Prostaglandins were determined by bioassay after organic solvent extraction and silicic acid chromatography of the incubates. Mono-7-HR, di-HR and HR stimulated the biosynthesis. In contrast, tri-7,3',4'-HR and tetra-HR inhibited the formation of prostaglandins. Previously effects have been reported on inflammatory reactions and aggregation of thrombocytes by these compounds. Some of these effects may be explained by changes in the biosynthesis of prostaglandins.     

Modulation of antioxidant enzyme activities, platelet aggregation and serum prostaglandins in rats fed spray-dried milk containing n-3 fatty acid

Spray-dried milk enriched with n-3 fatty acids from linseed oil or fish oil were fed to rats to study its influence on liver lipid peroxides, hepatic antioxidant enzyme activities, serum prostaglandins and platelet aggregation. Significant level of α linolenic acid, eicosapentaenoic acid and docosahexaenoic acid were accumulated at the expense of arachidonic acid in the liver of rats fed n-3 fatty acid enriched formulation. The linseed oil and fish oil enriched formulation fed group had 44 and 112% higher level of lipid peroxides in liver homogenate compared to control rats fed groundnut oil enriched formulation. Catalase activity in liver homogenate was increased by 37 and 183% respectively in linseed oil and fish oil formulation fed rats. The glutathione peroxidase activity decreased to an extent of 25–36% and glutathione transferase activity increased to an extent of 34–39% in rats fed n-3 fatty acids enriched formulation. Feeding n-3 fatty acid enriched formulation significantly elevated the n-3 fatty acids in platelets and increased the lipid peroxide level to an extent of 4.2–4.5 fold compared to control. The serum thromboxane B₂ level was decreased by 35 and 42% respectively in linseed oil and fish oil enriched formulation fed rats, whereas, 6-keto- prostaglandin F1α level was decreased by 17 and 23% respectively in linseed oil and fish oil enriched formulation fed rats. The extent and rate of platelet aggregation was decreased significantly in n-3 fatty acids enriched formulation fed rats. This indicated that n-3 fatty acids enriched formulation beneficially reduces platelet aggregation and also enhances the activities of hepatic antioxidant enzymes such as catalase and glutathione transferase. (Mol Cell Biochem xxx: 9–16, 2005)     

Stimulation and inhibition of biosynthesis of prostaglandins in human skin by some hydroxyethylated rutosides

The effect of some hydroxyethylated rutosides on the biosynthesis of prostaglandins was studied in the microsomal fraction of human skin homogenates. Microsomes were incubated with mono-0-hydroxyethyl-7-rutoside (mono-7-HR), di-0-hydroxyethyl-7′,4′-rutoside (di-HR), tri-0-hydroxyethyl-7,3′,4′-rutoside (tri-7,3′,4′-HR), tetra-0-hydroxyethyl-5,7,3′,4′-rutoside (tetra-HR) and a mixture of hydroxyethylated compounds (HR). Prostaglandins were determined by bioassay after organic solvent extraction and silicic acid chromatography of the incubates. Mono-7-HR, di-HR and HR stimulated the biosynthesis. In contrast, tri-7,3′,4′-HR and tetra-HR inhibited the formation of prostaglandins. Previously effects have been reported on inflammatory reactions and aggregation of thrombocytes by these compounds. Some of these effects may be explained by changes in the biosynthesis of prostaglandins.     

Activation of arachidonic acid]

Intravenous injection of arachidonic acid induces cardiovascular and respiratory effects due to its transformation into prostaglandins, This activation could take place not only in the platelets but also in the vacular wall. Platelet aggregation induced by arachidonic acid is not the main factor responsible of its cardiovascular actions.     

Disorders in the thrombocyte link of hemostasis during endotoxinemia and their correction with the inhibitor of prostaglandin biosynthesis, indomethacin

After 10 minutes of endotoxin Salmonella typhimurium (1 mg/kg) injection into rabbits thrombocytopenia appeared, the aggregation and secretory function of circulating platelets reduced, the transformation of platelet forms from disk-shaped into spheroidal took place. On the surface of plasmatic membranes the pseudopodies and aggregates examining samples of PRP were observed. Indomethacin, blockator of biosynthesis of prostaglandins results in normalisation of morphofunctional properties of platelets.     

Prostaglandin E2: Effects on aggregation,shape change and cyclic AMP of rat platelets

PGE₂ inhibits intracellular cyclic AMP accumulation induced by PGE₁ in rat platelets. PGE₂ also counteracts PGE₁-inhibition of both platelet aggregation and shape change. However, in the presence of theophylline, PGE₂ acts like PGE₁ in inhibiting aggregation. The mechanism of interaction of the two closely related prostaglandins is discussed.     

Interaction of prostaglandins with blood plasma proteins. Comparative binding of prostaglandins A2, F2α and E2 to human plasma proteins

1. The binding of prostaglandin A(2) and prostaglandin F(2alpha) to human plasma proteins was investigated by DEAE-Sephadex chromatography and polyacrylamide-gel electrophoresis. Both prostaglandins, when added to human plasma in vitro, were found to become bound mainly to plasma albumin. 2. The extent of binding of prostaglandins added to human plasma in low to moderate concentrations was found to be approx. 88, 73 and 58% for prostaglandins A(2), E(2) and F(2alpha) respectively. The order of affinities for the binding of the three prostaglandins to albumin appear to be A(2)>E(2)>F(2alpha). 3. The apparent association constants for the binding of these prostaglandins to human serum albumin were estimated to be approx. 4.8x10(4), 2.4x10(4) and 0.9x10(4) litre/mol for prostaglandins A(2), E(2) and F(2alpha) respectively. The results are compared with previously reported association constants for the binding of long-chain fatty acids to both human and bovine albumins.     

Coronary vasoconstrictor extracted from blood plasma stimulates platelet lipoxidase activity

The effects of a coronary vasoconstrictor, obtained from human blood plasma, on aggregation and arachidonate metabolism by human platelets was determined. At low concentrations, the vasoactive factor stimulated formation of prostaglandins, thromboxane B₂, and 12-L-hydroxyeicosatetraenoic acid in both intact platelets and in platelet microsomal enzyme preparations. As factor concentration was increased, thromboxane B₂ formation decreased, but production of the other products continued to rise. Low concentrations of factor initiated platelet aggregation, whereas high concentrations prevented arachidonate-induced aggregation. Low levels of factor could induce aggregation via stimulation of thromboxane A₂ production. Increases in formation of 12-hydroperoxyeicosatetraenoic acid at high factor concentrations could inhibit formation of thromboxane A₂ and thus prevent aggregation.     

Desensitization of prostaglandin-activated platelet adenylate cyclase.

Prostaglandin D2 (PGD2) is one of several prostaglandins that can inhibit platelet aggregation and activate adenylate cyclase. Platelets were exposed to varying concentrations of PGD2 washed, and the adenylate cyclase response to prostaglandins, epinephrine, and sodium fluoride determined. Incubating platelets with 5 x 10(-5) M PGD2 for 2 hr resulted in a 45% decrease in PGD2 activation of adenylate cyclase and a 25% decrease in stimulation by PGE1. Fluoride activation (7-fold) epinephrine inhibition (30%) and basal enzyme activity were unchanged by exposure of the platelets to PGD2. Desensitization was concentration dependent, with loss of enzyme activity first noted when platelets were incubated with 10(-7) M PGD2. Enzyme sensitivity could be partially restored when desensitized platelets were washed free of PGD2 and incubated in buffer for 2 hr; complete resensitization required incubation for 24 hr in plasma. Regulation of prostaglandin sensitive platelet adenylate cyclase could be of importance in mediating the response of platelets to aggregating agents.     

Appraisal of casein's inhibitory effects on aggregation accompanying carbonic anhydrase refolding and heat-induced ovalbumin fibrillogenesis

It is well accepted that whole casein and its purified major components, due to their chaperone-like activity, are able to suppress the thermal and chemical aggregation of several substrate proteins. In this study, we set out to determine whether whole and β-casein are able to prevent (or attenuate) aggregation accompanying refolding of chemically denatured carbonic anhydrase or to recover lost biological activity after its denaturation. Additionally, we showed attenuated heat-induced fibrillar aggregation of egg white ovalbumin in the presence of these commonly occurring unfolded proteins, as molecular chaperones. Also, the extent, rate and order of aggregation, in the presence and absence of aggregation suppressors, were compared. Although β-casein did not prevent aggregation as strong as whole casein, both chaperones were efficient not only in suppressing the aggregation extent of denatured carbonic anhydrase, but also in delaying elongation process of amyloid fibril formation with no effect on nucleation phase.     

A potent platelet aggregation inducer from Trimeresurus gramineus snake venom

A potent platelet aggregation inducer (platelet aggregoserpentin) was purified from Trimeresurus gramineus snake venom by DEAE-Sephadex A-50 and Sephacryl S-300 column chromatography. It was homogeneous as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. It elicited dose-dependently platelet aggregation and serotonin release reaction in rabbit platelet-rich plasma and platelet suspension. Exogenous calcium was required for its activity. Creatine phosphate/creatine phosphokinase and apyrase showed no significant inhibitory effect on aggregoserpentin-induced platelet aggregation in platelet suspension. Aggregoserpentin induced aggregation in ADP-refractory platelet-rich plasma. It caused no detectable malonic dialdehyde formation in the process of platelet aggregation. Indomethacin did not inhibit aggregoserpentin-induced platelet aggregation. Mepacrine abolished preferentially its aggregating activity, while prostaglandin E1 completely blocked both aggregoserpentin-induced aggregation and release reaction. Furthermore, platelet aggregoserpentin lowered basal and prostaglandin E1-stimulated cAMP levels in platelet suspension. Nitroprusside inhibited both its aggregating and releasing activity, while verapamil preferentially blocked its aggregating activity. It is concluded that aggregoserpentin activated platelets through lowering cAMP levels or the activation of endogenous phospholipase A2, resulting in the formation of platelet activating factor, but not of prostaglandins.     

Effect of La(3+) on electrophoretic mobility and aggregation of intact human erythrocytes and those treated with low concentrations of glutaric aldehyde

It was shown that the treatment of erythrocytes with low concentrations of glutaraldehyde (0.01-0.1%) for 30-120 min to a variable extent the aggregation induced by 40-330 microM La3+. The effect of glutaraldehyde on the aggregation increased with concentration and time of fixation. La3+ ions decreased to a similar extent the electrophoretic mobility of intact erythrocytes and erythrocytes treated with 0.1% glutaraldehyde. No relationship was found between the change in the negative charge on the erythrocytes and the degree of their aggregation. Neuraminidase and trypsin were shown to decrease the surface charge on the erythrocytes and the aggregation of fixed erythrocytes.